Dyne Therapeutics (DYN) to Release Earnings on Monday

Dyne Therapeutics (NASDAQ:DYN) will likely be posting its Q2 2026 results before the market opens on Monday, July 27th. Analysts expect Dyne Therapeutics to announce earnings of ($0.74) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 9:30 AM ET.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the company posted ($1.05) EPS. On average, analysts expect Dyne Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dyne Therapeutics Price Performance

DYN stock opened at $23.74 on Monday. The firm’s fifty day simple moving average is $19.82 and its 200-day simple moving average is $18.45. The company has a market capitalization of $3.92 billion, a P/E ratio of -7.37 and a beta of 1.06. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics has a 12 month low of $8.88 and a 12 month high of $25.00.

Insiders Place Their Bets

In related news, Director Jason P. Rhodes sold 480,240 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $22.79, for a total value of $10,944,669.60. Following the transaction, the director directly owned 875,912 shares in the company, valued at approximately $19,962,034.48. This represents a 35.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have bought 9,000 shares of company stock valued at $156,800 and have sold 2,839,681 shares valued at $58,622,401. 9.46% of the stock is owned by insiders.

Institutional Trading of Dyne Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd purchased a new position in Dyne Therapeutics during the 4th quarter valued at about $84,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the period. Tower Research Capital LLC TRC increased its stake in Dyne Therapeutics by 275.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares during the period. Prudential Financial Inc. purchased a new stake in Dyne Therapeutics during the 2nd quarter worth approximately $111,000. Finally, Creative Planning lifted its holdings in Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after buying an additional 2,797 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on DYN. Sanford C. Bernstein lifted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, July 6th. Evercore set a $33.00 price target on Dyne Therapeutics in a report on Friday, May 15th. TD Cowen assumed coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.